Oral Hydralazine Dosing When IV Administration is Not Feasible
When IV hydralazine 10 mg cannot be administered due to lack of venous access, an oral hydralazine dose of 25-50 mg should be used as an appropriate substitute. 1
Pharmacokinetics and Bioavailability Considerations
- Hydralazine has lower bioavailability when administered orally (26-55% of the dose reaches systemic circulation as unchanged drug) due to first-pass metabolism 2
- Oral hydralazine undergoes extensive hepatic metabolism with peak plasma levels reached at 1-2 hours after administration 3
- The half-life of hydralazine is 3-7 hours, with significant variability among individuals due to polymorphic acetylation (slow acetylators generally have higher plasma levels) 3
Dosing Recommendations
Initial Oral Dosing
- For acute management when IV administration is not possible:
Maintenance Dosing
- For ongoing management:
Clinical Considerations and Precautions
Onset and Duration of Action
- Blood pressure begins to decrease within 10-30 minutes after IV administration, with effects lasting 2-4 hours 1
- Oral administration will have a somewhat delayed onset compared to IV administration 3
- The unpredictability of response and prolonged duration of action make hydralazine less desirable as a first-line agent for acute hypertension management 1
Adverse Effects and Monitoring
- Common adverse effects include reflex tachycardia due to peripheral vasodilation 4
- Serious but less common adverse effects include:
- Monitor for excessive hypotension, especially when combined with other antihypertensive medications 3
Special Considerations
- Tolerance to the vasodilator effect may develop during long-term oral therapy, potentially reducing efficacy 5
- Food increases plasma levels of hydralazine, which may affect dosing considerations 3
- Hydralazine is available in 10 mg, 25 mg, 50 mg, and 100 mg oral tablet formulations 3
Practical Algorithm for Oral Substitution of IV Hydralazine
For acute management when 10 mg IV hydralazine would be indicated:
If additional doses are needed:
For transition to maintenance therapy: